drugset / Trial / NCT01485757

Prospective L-arginine Study

NCT01485757

Phase 1 Terminated 3 enrolled University of Michigan
NaSingle-groupOpen-labelTreatment

Summary

HYPOTHESIS The investigators primary hypothesis is that peripheral endothelial function and exercise tolerance will be abnormal in the population of young heart transplant patients at baseline, and that each will show a trend towards improvement following a 12 week course of oral L-arginine, with regression towards the baseline following the 12 week washout period.

Timeline

Start
2011-07
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject L-arginine Small molecule 3 g Oral

Indications

No indication recorded.